ASCO 2025 Poster Presentation: A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab For First-Line Treatment of PD-L1-Positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The FORTIFI-HN01 Study